About: Aluminum Nanoparticles Acting as a Pulmonary Vaccine Adjuvant-Delivery System (VADS) Able to Safely Elicit Robust Systemic and Mucosal Immunity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Aluminum Nanoparticles Acting as a Pulmonary Vaccine Adjuvant-Delivery System (VADS) Able to Safely Elicit Robust Systemic and Mucosal Immunity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Aluminum Nanoparticles Acting as a Pulmonary Vaccine Adjuvant-Delivery System (VADS) Able to Safely Elicit Robust Systemic and Mucosal Immunity
Creator	Wang, Ning Wang, Ting Liu, Ting Wei, Chunliu Zhang, Zina
Source	Medline; PMC
abstract	ABSTRACT: Vulnerability of respiratory mucosa to invasions of airborne pathogens, such as SARS-CoV, MERS-CoV and avian viruses which sometimes cause a life-threatening epidemic and even pandemic, underscores significance of developing a pulmonary vaccine adjuvant-delivery system (VADS). Herein, 30-nm aluminum nanoparticles (ANs), unlike the mostly used adjuvant alum which is unsuitable for delivering pulmonary vaccines due to side effects, proved able to act as a VADS fitting inhalation immunization to elicit wide-spread anti-antigen immunity. In vitro ANs facilitated cellular uptake of their cargos and, after pulmonary vaccination, induced mouse production of high levels of anti-antigen IgG in serum and IgA in saliva, nasal, bronchoalveolar and also vaginal fluids. Besides, IFN-γ and anti-antigen IgG2a enriched in immunized mice which meanwhile showed no obvious lung inflammation indicated balanced Th1/Th2 responses were safely induced. These outcomes suggest ANs may be an efficient pulmonary VADS for defending against pathogens, especially, the ones invading hosts via respiratory system. GRAPHIC ABSTRACT: Aluminum nanoparticles can safely induce humoral and cellular immunity at systemic and mucosal level through pulmonary vaccination to contrast the conventional adjuvant alum. [Image: see text]
has issue date	2020-05-09(xsd:dateTime)
bibo:doi	10.1007/s10904-020-01572-z
bibo:pmid	32395098
has license	no-cc
sha1sum (hex)	bdd6cfab8f16d2b6cd0880a9b486042aa0f35be6
schema:url	https://doi.org/10.1007/s10904-020-01572-z
resource representing a document's title	Aluminum Nanoparticles Acting as a Pulmonary Vaccine Adjuvant-Delivery System (VADS) Able to Safely Elicit Robust Systemic and Mucosal Immunity
has PubMed Central identifier	PMC7210793
has PubMed identifier	32395098
schema:publication	J Inorg Organomet Polym Mater
resource representing a document's body	covid:bdd6cfab8f16d2b6cd0880a9b486042aa0f35be6#body_text
is schema:about of	named entity 'SARS-CoV' named entity 'vaccines' named entity 'obvious' named entity 'aluminum' named entity 'epidemic' named entity 'Vaccine' named entity 'Immunity' named entity 'MAY BE' named entity 'MICE' named entity 'SUGGEST' named entity 'MOUSE PRODUCTION' named entity 'ALUMINUM' named entity 'LEVELS' covid:arg/bdd6cfab8f16d2b6cd0880a9b486042aa0f35be6 named entity 'ANs' named entity 'respiratory system' named entity 'vaccine' named entity 'production' named entity 'avian' named entity 'immunity' named entity 'ANs' named entity 'efficient' named entity 'induced' named entity 'pulmonary' named entity 'lung inflammation' named entity 'side effects' named entity 'VADS' named entity 'nasal' named entity 'Able' named entity 'respiratory mucosa' named entity 'saliva' named entity 'immunization' named entity 'vaccine adjuvant' named entity 'mice' named entity 'pathogens' named entity 'pathogens' named entity 'vaccination' named entity 'vaginal fluids' named entity 'nanoparticles' named entity 'antigen' named entity 'vaccines' named entity 'alum' named entity 'Mucosal Immunity' named entity 'developing' named entity 'OVA' named entity 'Darmstadt' named entity 'lysosomal degradation' named entity 'RPMI 1640' named entity 'SARS' named entity 'mAb' named entity 'tumor' named entity 'quarantining' named entity 'mucosa' named entity 'microbe' named entity 'OVA' named entity 'CD86' named entity 'vaccine' named entity 'vaccination' named entity 'biomarkers' named entity 'mice' named entity 'cell membranes' named entity 'OVA' named entity 'SPSS' named entity 'SEM' named entity 'CD4' named entity 'IgG1' named entity 'APCs' named entity 'vaccine adjuvant' named entity 'costimulatory signals' named entity 'mucosal immunity' named entity 'SARS-CoV2' named entity 'PBS' named entity 'China' named entity 'bronchi' named entity 'PBS' named entity 'histopathological' named entity 'zeta potential'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software